<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00663897</url>
  </required_header>
  <id_info>
    <org_study_id>OMCP-97-007</org_study_id>
    <nct_id>NCT00663897</nct_id>
  </id_info>
  <brief_title>Lansoprazole Versus Mosapride for Functional Dyspepsia</brief_title>
  <official_title>A Comparative Study of Lansoprazole and Mosapride for Functional Dyspepsia: Focus on Difference Between Epigastric Pain Syndrome and Postprandial Distress Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lotung Poh-Ai Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tomorrow Medical Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Lotung Poh-Ai Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Functional dyspepsia is a common symptom complex with significant impact on quality of life.
      There is no standard treatment for functional dyspepsia but therapeutic efficacy of proton
      pump inhibitor (PPI) and prokinetic agent have been proved in subsets of patients. This study
      has two aims:

        -  first is to compare the therapeutic efficacy of lansoprazole (a PPI) and mosapride (a
           prokinetic agent) for functional dyspepsia

        -  second is to investigate whether different subgroups of functional dyspepsia (e.g.,
           epigastric pain syndrome and postprandial distress syndrome) respond differently to PPI
           and prokinetic agent.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible outpatients with presentation of dyspepsia are enrolled if they fulfilled the
      criteria of ROME III criteria. A trained assistant helps the eligible patients to complete
      the ROME III standard questionaire, brief symptom rating scale (BSRS), and Maudsley
      Personality Inventory (MPI). The enrolled patients are then randomized into either
      lansoprazole or mosapride group for 14-day treatment. Before starting medication, right after
      completing the medication, and 1 month after the medication, the enrolled patients complete
      standardized severity questionnaire (Hong-Kong Index) to evaluate severity of dyspeptic
      symptoms. Symptom improvement is then determined.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement of dyspeptic symptoms as evaluated by validated questionnaire</measure>
    <time_frame>After 2-week treatment of lansoprazole or mosapride</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">329</enrollment>
  <condition>Functional Dyspepsia</condition>
  <condition>Epigastric Pain Syndrome</condition>
  <condition>Post Prandial Distress Syndrome</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with lansoprazole (30 mg) once daily for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment with mosapride (5 mg) thrice daily for 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lansoprazole</intervention_name>
    <description>lansoprazole, 30 mg, once daily for 14 days</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Takepron (brand name)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mosapride</intervention_name>
    <description>mosapride, 5 mg, thrice daily for 14 days</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Mopride (brand name)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  aged more than 20 years old

          -  diagnosis of functional dyspepsia by fulfilling Rome-III criteria

          -  outpatient

        Exclusion Criteria:

          -  aged less than 20 years

          -  organic lesions including ulcers, tumors, bleeding, vasculopathy or esophagitis as
             demonstrated on upper endoscopy

          -  concurrent illness with malignancy, diabetes mellitus, liver cirrhosis, renal failure
             or porphyria

          -  diagnosis of organic disease for dyspeptic symptoms by treating physicians

          -  history of abdominal surgery

          -  concurrent user of aspirin and NSAID

          -  history of allergy or severe side effects to lansoprazole or mosapride

          -  pregnant or lactating women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yao-Chun Hsu, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lotung Poh-Ai hospital, I-Lan County, Taiwan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lotung Poh-Ai hospital</name>
      <address>
        <city>Lotung Town, Ilan county</city>
        <zip>26546</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <link>
    <url>http://www.romecriteria.org/</url>
    <description>The homepage of ROME foundation, an non-for-profit organization dedicated to scientific research and education information of functional gastrointestinal disorders (FGIDs).</description>
  </link>
  <verification_date>October 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 21, 2008</study_first_submitted>
  <study_first_submitted_qc>April 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2008</study_first_posted>
  <last_update_submitted>October 8, 2009</last_update_submitted>
  <last_update_submitted_qc>October 8, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 9, 2009</last_update_posted>
  <responsible_party>
    <name_title>Hsing-Hong Chen/Superintendent</name_title>
    <organization>Lotung Poh-Ai hospital</organization>
  </responsible_party>
  <keyword>functional dyspepsia</keyword>
  <keyword>epigastric pain syndrome</keyword>
  <keyword>postprandial distress syndrome</keyword>
  <keyword>proton pump inhibitor</keyword>
  <keyword>5 HT-4 receptor agonist</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Somatoform Disorders</mesh_term>
    <mesh_term>Dyspepsia</mesh_term>
    <mesh_term>Gastritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lansoprazole</mesh_term>
    <mesh_term>Dexlansoprazole</mesh_term>
    <mesh_term>Mosapride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

